Home
July 2008 August 2008 September 2008
Su Mo Tu We Th Fr Sa
Week 31 1 2
Week 32 3 4 5 6 7 8 9
Week 33 10 11 12 13 14 15 16
Week 34 17 18 19 20 21 22 23
Week 35 24 25 26 27 28 29 30
Week 36 31

Surgical Management of Pelvic Organ Prolapse in Women: A Short Version Cochrane Review - Abstract Show Comments PDF Print E-mail
  
Friday, 25 January 2008

Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004014. DOI: 10.1002/14651858.CD004014.pub3 Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

Pelvic organ prolapse may occur in up to 50% of parous women. A variety of urinary, bowel and sexual symptoms may be associated with prolapse.

To determine the effects of the many different surgeries in the management of pelvic organ prolapse

We searched the Cochrane Incontinence Group Specialised Trials Register (searched 3 May 2006) and reference lists of relevant articles. We also contacted researchers in the field.

Randomised or quasi-randomised controlled trials that included surgical operations for pelvic organ prolapse

Trials were assessed and data extracted independently by two reviewers. Six investigators were contacted for additional information with five responding.

Twenty two randomised controlled trials were identified evaluating 2368 women.Abdominal sacral colpopexy was better than vaginal sacrospinous colpopexy in terms of a lower rate of recurrent vault prolapse (RR 0.23, 95% CI 0.07 to 0.77) and less dyspareunia (RR 0.39, 95% CI 0.18 to 0.86), but the trend towards a lower re-operation rate for prolapse following abdominal sacrocolpopexy was not statistically significant (RR 0.46, 95% CI 0.19 to 1.11). However, the vaginal sacrospinous colpopexy was quicker and cheaper to perform and women had an earlier return to activities of daily living. The data were too few to evaluate other clinical outcomes and adverse events. The three trials contributing to this comparison were clinically heterogeneous. For the anterior vaginal wall prolapse, standard anterior repair was associated with more recurrent cystoceles than when supplemented by polyglactin mesh inlay (RR 1.39, 95% CI 1.02 to 1.90) or porcine dermis mesh inlay (RR 2.72, 95% CI 1.20 to 6.14), but data on morbidity, other clinical outcomes and for other mesh or graft materials were too few for reliable comparisons. For posterior vaginal wall prolapse, the vaginal approach was associated with a lower rate of recurrent rectocele and/or enterocele than the transanal approach (RR 0.24, 95% CI 0.09 to 0.64), although there was a higher blood loss and postoperative narcotic use. However, data on the effect of surgery on bowel symptoms and the use of polyglactin mesh inlay or porcine small intestine graft inlay on the risk of recurrent rectocele were insufficient for meta-analysis.Meta-analysis on the impact of pelvic organ prolapse surgery on continence issues was limited and inconclusive, although about 10% of women developed new urinary symptoms after surgery. Although the addition of tension-free vaginal tape to endopelvic fascia plication (RR 5.5, 95% CI 1.36 to 22.32) and Burch colposuspension to abdominal sacrocolpopexy (RR 2.13, 95% CI 1.39 to 3.24) were followed by a lower risk of women developing new postoperative stress incontinence, but other outcomes, particularly economic, remain to be evaluated.

Abdominal sacrocolpopexy is associated with a lower rate of recurrent vault prolapse and dyspareunia than the vaginal sacrospinous colpopexy. These benefits must be balanced against a longer operating time, longer time to return to activities of daily living and increased cost of the abdominal approach. The use of mesh or graft inlays at the time of anterior vaginal wall repair may reduce the risk of recurrent cystocele. Posterior vaginal wall repair may be better than transanal repair in the management of rectoceles in terms of recurrence of prolapse. The addition of a continence procedure to a prolapse repair operation may reduce the incidence of postoperative urinary incontinence but this benefit needs to be balanced against possible differences in costs and adverse effects. Adequately powered randomised controlled clinical trials are urgently needed. Neurourol. Urodynam. (c) 2007 Wiley-Liss, Inc.

Written by
Maher C, Baessler K, Glazener CM, Adams EJ, Hagen S.

Reference
Neurourol Urodyn. 2008 Jan;27(1):3-12
doi:10.1002/nau.20542

PubMed Abstract
PMID:18092333

UroToday.com Urinary Incontinence (UI) Section

UroToday.com Female Urology Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >